PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/562,951

Filing Date December 23, 2005

First Named Inventor Brian Anderton, et al.

TATEMENT BY APPLICANT
(Use as many sheets as necessary)

First Named Inventor Brian Anderton, et al.

Art Unit Not yet assigned

Examiner Name Not yet assigned

Attorney Docket Number 0380-P03923US0

Sheet **U. S. PATENT DOCUMENTS** Examiner Cite Document Number **Publication Date** Name of Patentee or , Columns, Lines, Where Initials* No. MM-DD-YYYY Applicant of Cited Document vant Passages or Relevant -Kind Code^{2 (# known)} Figures Appear Numb US-US-บร-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ Number ⁴ Kind Code (if known)	MM-DD-YYYY			T ⁶
	<u> </u>					

Examiner Signature Date Considered

*EXAMINER: initial if eference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese pater documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (3nd by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Parent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND OC. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/562,951	
INFORMATION DISCLOSURE	Filing Date	December 23, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Brian Anderton, et al.	
(Use as many sheets as necessary)	Art Unit	Not yet assigned	
(Usa as many sneets as necessary)	Examiner Name	Not yet assigned	
Sheet 2 of 3	Attorney Docket Number	0380-P03923US0	

		NON PATENT LITERATURE DOCUMENTS	Ť		
Examiner Initials*	examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of				
		HANGER, D. et al., "New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament-Tau) from," Journal of Neurochemistry, 71:2465-2476, (1998)			
		LAMBERT, M. et al., "Diffusible, nonfibrillar ligands derived from AB1-42 are potent central nervous system neurotoxins," Proc. Natl. Acad. Sci., 95:6448-6453, (1998)			
	LEE, V. et al., "Neurodegenerative Tauopathies," Annu. Rev. Neurosci., 24:1121-1159, (2001)				
		MULOT, S. et al., "PHF-tau from ALIzheimer's brain comprises four species on SDS-PAGE which can be," Federation of European Biochemical Societies, 349:359-364, (1994)			
		SHIRAZI, S. et al., "The protein tyrosine kinase, fyn, in Alzheimer's disease pathology," Neuro Report, 4:435-437, (1993)			
		SINGH, T. et al., "Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by," Federation of European Biochemical Societies, 358:4-8, (1995)			
		SINGH, T. et al., "Rapid Alzheimer-like phosphorylation of tau by the synergistic actions," Federation of European Biochemical Societies, 358:267-272, (1995)			
		WILLIAMSON, R. et al., "Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in," The Journal of Neuroscience, 22(1):10-20 (2002)			
		GOEDERT, M. et al., "Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four," The EMBO Journal, 8(2):393-399 (1989)			

Examiner	Date	
Signature	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known				
				Application Number	10/562,951	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 23, 2005	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Brian Anderton, et al.	
(Use as many sheets as necessary)				Art Unit	Not yet assigned	
(ose as many sneeds as necessary)			ecessary)	Examiner Name	Not yet assigned	
Sheet	3	of	3	Attorney Docket Number	0380-P03923US0	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOEDERT, M. et al., "Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and," The EMBO Journal, 9(13):4225-4230, (1990)	
		GRAVES, P. et al., "Molecular Cloning, Expression, and Characterization of a 49-Kilodalton Casein," The Journal of Biological Chemistry, 268(9):6394-6401, (1993)	
·		GOEDERT, M. et al., "Multiple Isoforms of Human Microtubule-Associated Protein Tau: Sequences and Localization in Neurofibrillary Tangles of," Neuron., 3:519-526, (1989)	
		SCALES, T. et al., "Tyrosine Phosphorylation of Specific Sites on Tau by SRC Family Kinases," Neurobiol. Aging, 23:S500-S501, (2002)	
•			

Examiner		Date	
Signature	/David Steadman/	Considered	09/12/2008

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.